|
|
Blood, Vol. 113, Issue 9, 2096-2103, February 26, 2009
Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes
Blood Kuwatsuka et al.
113: 2096
Supplemental materials for: Kuwatsuka et al
Files in this Data Supplement:
- Table S1. GVHD prophylaxis for CBF AML (PDF, 41.3 KB)
- Table S2. Outcome of the AML patient population by cytogenetic risk groups (BM/PB vs cord blood) (PDF, 43.9 KB)
- Figure S1. Over-all survival of patients between cytogenetic subgroups excluding cord blood transplant (JPG, 70.6 KB)
-
(A) Survival curves of patients undergoing allogeneic SCT in first CR, and (B) survival curve of patients undergoing allogeneic SCT in second or third CR, (C) survival curves of patients undergoing allogeneic SCT not in CR, each categorized by cytogenetic risk groups, respectively. Survival curves are almost the same as those in Fig. 1.
- Figure S2. Over-all survival of CBF patients excluding cord blood transplant (JPG, 52.9 KB)
-
(A) Survival curves of patients with t(8;21) and, (B) with inv(16). Both stratified according to the type (allogeneic or autologous) and disease status at the time of transplant (CR, second or third CR, and not in CR). Survival curves are almost the same as those in Fig. 3.
|
|
